Foghorn Therapeutics Inc.

NASDAQ:FHTX

Biotechnology

Healthcare
$1.79 +2.35%

+$0.10 today

Market cap
$107.33M
Beta
2.89
P/E (TTM)
-3.8
EPS (TTM)
-$1.08
52W Low $3.27High $6.95

Volume 0.53M

Average 0.15M

Income Statement

Follow revenue through to earnings.

Revenue

$30.91M

FY 2025 · Annual

+36.8% YoY

Operating Income

-$82.11M

FY 2025 · Annual

Net Income

-$74.28M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.32M19.23M34.16M22.6M30.91M
Cost of Revenue00003.33M
Gross Profit1.32M19.23M34.16M22.6M27.58M
Gross Margin100.0%100.0%100.0%100.0%89.2%
Research & Development80.33M105.62M109.69M94.53M85.47M
Selling, General & Admin21.73M30.75M32.37M28.36M27.55M
Operating Expenses102.05M136.37M142.06M125.29M109.68M
Depreciation & Amortization3.23M3.32M3.45M3.12M3.33M
EBITDA(96.19M)(105.56M)(90.75M)(97.17M)(70.95M)
EBITDA Margin-7292.4%-549.0%-265.7%-429.9%-229.5%
Operating Income(100.73M)(117.14M)(107.91M)(102.68M)(82.11M)
Operating Margin-7637.1%-609.2%-315.9%-454.3%-265.6%
Interest Income59K5.68M10.88M11.9M8.75M
Interest Expense1.91M0000
Other Income / Expenses(586K)8.26M13.71M16.06M7.82M
Income Before Tax(101.32M)(108.88M)(94.2M)(86.62M)(74.28M)
Pre-Tax Margin-7681.6%-566.3%-275.8%-383.2%-240.3%
Income Tax Expense004.23M00
Net Income(101.32M)(108.88M)(98.43M)(86.62M)(74.28M)
Net Margin-7681.6%-566.3%-288.2%-383.2%-240.3%
EPS (Basic)(2.78)(2.62)(2.34)(1.58)(1.18)
EPS (Diluted)(2.78)(2.62)(2.34)(1.58)(1.18)
Weighted Avg Shares37.17M41.59M41.97M54.9M62.98M
Weighted Avg Shares (Diluted)37.17M41.59M41.97M54.9M62.98M

FHTX Earnings Waterfall · TTM

NASDAQ:FHTX · Revenue to Net Income

Key Ratios

EPS$-1.17
Gross Margin31.7%
Net Margin-318.6%
P/E Ratio-4.3
P/S Ratio53.9

Analysis

$28.2M of revenue converted into -$75.3M of net income for the selected period. Gross margin is 31.7% and net margin is -318.6%, showing how much revenue survives after costs and taxes. EPS is $-1.17, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
3Initial statement of beneficial ownershipOct 5, 2026
SC 13G/ASC 13G/A filingOct 5, 2026
8-KCurrent reportOct 1, 2026

How much revenue does FHTX generate?

Foghorn Therapeutics Inc. (FHTX) reported $30.91M of revenue in fiscal 2025.

Is FHTX profitable?

Foghorn Therapeutics Inc. (FHTX) reported -$74.28M of net income, with a net margin of -240.3%.